US Stock MarketDetailed Quotes
NYMXF Nymox Pharmaceutical
- 0.075
- -0.075-49.93%
15min DelayClose Nov 29 13:00 ET
7.02MMarket Cap-751P/E (TTM)
0.140High0.070Low3.08KVolume0.080Open0.150Pre Close273.53Turnover0.01%Turnover RatioLossP/E (Static)93.54MShares1.40052wk High-2.21P/B3.40MFloat Cap0.00052wk Low--Dividend TTM45.29MShs Float13.625Historical High--Div YieldTTM46.67%Amplitude0.000Historical Low0.088Avg Price1Lot Size
About Nymox Pharmaceutical Company
Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert, TobacAlert and Fexapotide Triflutate for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.
Company Profile
SymbolNYMXF
Company NameNymox Pharmaceutical
Listing DateNov 26, 1997
Founded1995
CEODr. Paul Averback,M.D.,D.A.B.P.
MarketPink Market
Employees9
Fiscal Year Ends12-31
AddressBay & Deveaux Streets,2nd Floor
CityNassau
ProvinceNew Providence
CountryBahamas (the)
Phone1-800-936-9669
Websitehttp://www.nymox.com
Company Executives
- Name
- Position
- Salary
- Dr. Paul Averback,M.D.,D.A.B.P.
- Chairman of the Board, Chief Executive Officer and President
- 746.75K
- Erik Danielsen
- Chief Financial Officer
- --
- PatrickA. Doody
- Vice President and General Counsel
- --
- Paul Averback
- President and Director
- --
- Suresh Kalbag
- Director
- --
- James G. Robinson
- Director
- --
- David Morse
- Director
- --
- Randall Lanham
- Director and General Counsel
- 534.36K
- James G. Robinson
- Independent Director
- 3.97K
- Dr. David Morse, PhD
- Independent Director
- 3.97K
- Richard Cutler
- Independent Director
- 3.97K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data